GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (STU:2I9) » Definitions » Shiller PE Ratio

Karolinska Development AB (STU:2I9) Shiller PE Ratio : (As of Jun. 06, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Karolinska Development AB Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Karolinska Development AB Shiller PE Ratio Historical Data

The historical data trend for Karolinska Development AB's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karolinska Development AB Shiller PE Ratio Chart

Karolinska Development AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Karolinska Development AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Karolinska Development AB's Shiller PE Ratio

For the Biotechnology subindustry, Karolinska Development AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karolinska Development AB's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karolinska Development AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Karolinska Development AB's Shiller PE Ratio falls into.



Karolinska Development AB Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Karolinska Development AB's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Karolinska Development AB's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/132.2054*132.2054
=0.000

Current CPI (Mar. 2024) = 132.2054.

Karolinska Development AB Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.386 100.432 -0.508
201409 -0.238 100.161 -0.314
201412 -0.087 100.225 -0.115
201503 -0.452 99.950 -0.598
201506 -1.176 99.995 -1.555
201509 -0.049 100.228 -0.065
201512 -0.218 100.276 -0.287
201603 -0.179 100.751 -0.235
201606 -0.136 101.019 -0.178
201609 -0.031 101.138 -0.041
201612 -0.040 102.022 -0.052
201703 -0.044 102.022 -0.057
201706 -0.031 102.752 -0.040
201709 0.281 103.279 0.360
201712 0.043 103.793 0.055
201803 -0.027 103.962 -0.034
201806 0.042 104.875 0.053
201809 0.005 105.679 0.006
201812 0.021 105.912 0.026
201903 -0.024 105.886 -0.030
201906 0.010 106.742 0.012
201909 -0.019 107.214 -0.023
201912 0.380 107.766 0.466
202003 -0.059 106.563 -0.073
202006 0.001 107.498 0.001
202009 -0.082 107.635 -0.101
202012 0.043 108.296 0.052
202103 -0.014 108.360 -0.017
202106 0.122 108.928 0.148
202109 -0.001 110.338 -0.001
202112 -0.011 112.486 -0.013
202203 -0.012 114.825 -0.014
202206 -0.008 118.384 -0.009
202209 -0.016 122.296 -0.017
202212 0.005 126.365 0.005
202303 -0.009 127.042 -0.009
202306 0.008 129.407 0.008
202309 0.003 130.224 0.003
202312 -0.001 131.912 -0.001
202403 0.000 132.205 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Karolinska Development AB  (STU:2I9) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Karolinska Development AB Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Karolinska Development AB's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Karolinska Development AB (STU:2I9) Business Description

Traded in Other Exchanges
Address
TomtebodavAgen 23 A, Solna, SWE, SE-171 65
Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved and commercializes the innovations through the sale of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.

Karolinska Development AB (STU:2I9) Headlines

No Headlines